However, as seen in EMPEROR-Reduced, there is a signal that there may be an upper limit of HF severity beyond which the mortality benefits of SGLT2-inhibition plateaus, whilst morbidity benefits (reduced hospitalisations) remain robust throughout the entire spectrum of disease risk and severity. The gene discussed is SLC5A2; the disease is hydrops fetalis.